Skip to main content
Equibles
RLMD logo

RLMD · Relmada Therapeutics, Inc.

Track RLMD — free

Use RLMD with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about RLMD

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$4.80 +0.05 (+1.05%) At close · Aug 14
Market Cap
$512.02M
Shares
106.67M

Relmada Therapeutics, Inc. Earnings Call Transcripts

Every quarterly earnings call for Relmada Therapeutics, Inc. (RLMD) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY26 · Q2
2026-08-06
Q2 2026 Financial Results Conference Call
Diluted EPS
$-0.11
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-04
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-12
Relmada Therapeutics, Inc. Q1 FY2026 Earnings Call
Confident tone Intellectual property Phase 3 registrational program NDV01 Phase 2 efficacy data
Diluted EPS
$-0.22
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-19
Relmada Therapeutics, Inc. Q4 FY2025 Earnings Call
Confident tone Phase III RESCUE program NDV-01 clinical data and efficacy Regulatory and FDA considerations
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Relmada Therapeutics, Inc. Q3 FY2025 Earnings Call
Confident tone NDV-01 phase two data NMIBC market opportunity BCG-naive BRIDGE study / off-label potential
Diluted EPS
$-0.30
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Relmada Therapeutics, Inc. Q2 FY2025 Earnings Call
Confident tone NDV-01 Phase II 6-month data Sepranolone and Prader-Willi syndrome Pipeline advancement and upcoming trials
Diluted EPS
$-0.30
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Relmada Therapeutics, Inc. Q1 FY2025 Earnings Call
Confident tone NDV-01 for non-muscle invasive bladder cancer Sepranolone for CNS indications Competitive landscape in NMIBC
Diluted EPS
$-0.58
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
Relmada Therapeutics, Inc. Q4 FY2024 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Relmada Therapeutics, Inc. Q3 FY2024 Earnings Call
Positive tone REL-1017 Phase 3 program Reliance II interim analysis Futility and clinical significance threshold
Diluted EPS
$-0.72
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Relmada Therapeutics, Inc. Q2 FY2024 Earnings Call
Positive tone REL-1017 Phase 3 Program (Reliance II & Relight) Preplanned Interim Analysis REL-P11 Psilocybin Program for Metabolic Disease
Diluted EPS
$-0.59
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Relmada Therapeutics, Inc. Q1 FY2024 Earnings Call
Positive tone Phase III REL-1017 program execution Psilocybin modified-release program Site management and trial oversight
Diluted EPS
$-0.72
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-19
Relmada Therapeutics, Inc. Q4 FY2023 Earnings Call
Positive tone RELIGHT (Study 304) Phase 3 progress REL-1017 / RELIANCE II enrollment and protocol changes Modified-release psilocybin preclinical/Phase 1 program
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Relmada Therapeutics, Inc. Q3 FY2023 Earnings Call
Diluted EPS
$-0.73
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Relmada Therapeutics, Inc. Q2 FY2023 Earnings Call
Diluted EPS
$-0.84
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Relmada Therapeutics, Inc. Q1 FY2023 Earnings Call
Diluted EPS
$-0.87
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-23
Relmada Therapeutics, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Relmada Therapeutics, Inc. Q3 FY2022 Earnings Call
Diluted EPS
$-1.31
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Relmada Therapeutics, Inc. Q2 FY2022 Earnings Call
Diluted EPS
$-1.33
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Relmada Therapeutics, Inc. Q1 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-23
Relmada Therapeutics, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-09-30
Relmada Therapeutics, Inc. Q3 FY2021 Earnings Call
Diluted EPS
$-2.44
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Relmada Therapeutics, Inc. Q2 FY2021 Earnings Call
Diluted EPS
$-1.56
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
Relmada Therapeutics, Inc. Q1 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-23
Relmada Therapeutics, Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–24 of 24 earnings calls
Key facts CIK 1553643 CUSIP 75955J402 13F (30d) 126 filings 124 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)